Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394357 | 0.98 | POLB (0.45) | ELANEPOLBHPGDMCL1KCNK3 | |
| SCHEMBL5734309 | 0.98 | POLB (0.45) | ELANEPOLBHPGDMCL1KCNK3 | |
| SCHEMBL6858730 | 0.95 | MTNR1A (0.41) | ELANEPOLBHPGDMCL1KCNK3 | |
| SCHEMBL4425242 | 0.93 | ELANE (0.41) | ELANEGAAHTTALDH1A1 | |
| SCHEMBL12064486 | 0.81 | HRH3 (0.46) | LMNA | |
| SCHEMBL9966338 | 0.78 | POLB (0.45) | POLBHPGDRAB9A | |
| SCHEMBL18905527 | 0.78 | CHRM2 (0.38) | ELANEPOLBLMNA | |
| SCHEMBL23893550 | 0.78 | KDM1A (0.36) | ELANELMNA | |
| SCHEMBL17073070 | 0.78 | ELANE (0.33) | ELANEGAA | |
| SCHEMBL18856453 | 0.78 | MEN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296832-B2 | Anionic polymerization methods for producing functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2016-03-29 | — | — | US | claimed |
| CN-102725315-B | Anionic polymerization methods for producing functionalized polymers | BRIDGESTONE CO.,LTD. (JP) | 2014-10-22 | — | — | CN | claimed |
| EP-2504365-B1 | ANIONIC POLYMERIZATION METHODS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORP (JP) | 2014-05-14 | — | — | EP | claimed |
| US-20130030133-A1 | ANIONIC POLYMERIZATION METHODS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2013-01-31 | — | — | US | claimed |
| CN-102725315-A | Anionic polymerization methods for producing functionalized polymers | BRIDGESTONE CORP | 2012-10-10 | — | — | CN | claimed |
| EP-2504365-A1 | ANIONIC POLYMERIZATION METHODS FOR PRODUCING FUNCTIONALIZED POLYMERS | Bridgestone Corporation (JP) | 2012-10-03 | — | — | EP | claimed |
| WO-2011066405-A1 | ANIONIC POLYMERIZATION METHODS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2011-06-03 | — | — | WO | claimed |
| CN-113880871-B | Preparation method of saturated monoboron compound | 中国科学院兰州化学物理研究所 | 2022-08-23 | — | — | CN | disclosed |
| CN-113880871-A | Preparation method of saturated monoboron compound | 中国科学院兰州化学物理研究所 | 2022-01-04 | — | — | CN | disclosed |
| CN-111689956-B | Resolution method of quinine compound containing quaternary ammonium group | 银谷制药有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-111689956-A | Resolution method of quinine compound containing quaternary ammonium group | 银谷制药有限责任公司 | 2020-09-22 | — | — | CN | disclosed |
| US-9296832-B2 | Anionic polymerization methods for producing functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2016-03-29 | — | — | US | disclosed |
| CN-102725315-B | Anionic polymerization methods for producing functionalized polymers | BRIDGESTONE CO.,LTD. (JP) | 2014-10-22 | — | — | CN | disclosed |
| WO-2011066405-A1 | ANIONIC POLYMERIZATION METHODS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2011-06-03 | — | — | WO | disclosed |
| US-6835860-B2 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | MERCK & CO., INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030187291-A1 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | MERCK SHARP & DOHME CORP. | 2003-10-02 | — | — | US | disclosed |
| US-6372911-B1 | REACTING COMPOUND CONTAINING AT LEAST ONE CARBON-CARBON DOUBLE BOND WITH CARBAMATE IN AQUEOUS SOLVENT IN PRESENCE OF BASE, OSMIUM CATALYST, CO-OXIDANT, AND OPTIONALLY ASYMMETRIC LIGAND, TO FORM REACTION MIXTURE CONTAINING BETA-HYDROXY CARBAMATE | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| US-5708168-A | FOR TREATING OR PREVENTING NEURONAL LOSS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996015112-A1 | AZEPINE SYNTHESIS VIA A DIELS-ALDER REACTION | ACEA PHARMACEUTICALS, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5476933-A | Condensation, ring expansion | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187291-A1 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | IDE, MMP1, CYP3A4 | ELANE 689/4885POLB 379/4885HPGD 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.